NCT03874494View on ClinicalTrials.gov

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

371

Participants

Timeline

Start Date

November 27, 2019

Primary Completion Date

August 6, 2021

Study Completion Date

September 6, 2021

Conditions
Schizophrenia
Interventions
DRUG

Brexpiprazole

Brexpiprazole 2-4 mg/day

DRUG

Aripiprazole

Aripiprazole 10-20 mg/day

Trial Locations (1)

710061

No.15 Yanyin Road, Yanta District, Xi’an

Sponsors
All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY